Drug companies are continuing to sell anti-retrovirals at hugely inflated prices in South Africa with some branded drugs selling for up to eight times more than generic versions available worldwide but that are not yet manufactured locally. The price for an annual course of triple therapy consisting of AZT, 3TC and Nevirapine in South Africa would cost around R20 000 (around R1 700 per month) before VAT and the chemist’s mark-up is added. In contrast, the same course of generic ARVs would cost around R3 300 year (or R275 a month). The huge profit margins of the drug companies forms the basis of a complaint lodged last year at the Competition Commission by a group of people living openly with HIV/AIDS, health workers, labour and civil society.